Risk-adjusted Phase II clinical trial
A risk-adjusted Phase II clinical trial is an early-phase efficacy design that incorporates patient baseline risk strata — such as disease severity, prognostic score, or comorbidity burden — directly into the trial's stopping rules and sample size calculations. By conditioning response targets and futility/efficacy thresholds on risk group membership, the design avoids the bias that arises when a new therapy is evaluated in a population whose prognostic mix differs from the historical control on which the null hypothesis was based.
Rekod sumber
Petikan disalin secara verbatim daripada rekod sumber kaedah. Tiada pengesahan peringkat tuntutan disimpulkan daripadanya.
- Thall, P. F., & Simon, R. (1994). Practical Bayesian guidelines for phase IIB clinical trials. Biometrics, 50(2), 337–349. · DOI 10.2307/2533377
- Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10(1), 1–10. · DOI 10.1016/0197-2456(89)90015-9
Tuntutan yang dikurasi
Tuntutan disimpan dalam lejar bukti, setiap satu dengan penilaiannya sendiri.
Pandangan ini tidak mencipta penilaian tuntutan apabila lejar tiada.
Kaedah berkaitan
Dijana daripada graf kaedah dan ditunjukkan sebagai perhubungan yang dicadangkan mesin — tiada tuntutan bukti disimpulkan.
Graf perhubungan yang dijana tiada perhubungan keluar untuk kaedah ini.